Related Experiment Video
Updated: Oct 23, 2025
12:38
Three-dimensional Reconstruction of the Vascular Architecture of the Passive CLARITY-cleared Mouse Ovary
Published on: December 10, 2017
8.9K
A clearer view on ovarian clear cell carcinoma
Aglaja De Pauw1, Eline Naert1,2, Koen Van de Vijver3
1Department of Internal Medicine and Pediatrics, Medical Oncology, Ghent University Hospital, Ghent, Belgium.
Acta Clinica Belgica
|August 18, 2021
Summary
Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer subtype with distinct molecular features and poorer survival. Research must focus specifically on OCCC to improve diagnosis and treatment outcomes.
Area of Science:
- Gynecologic Oncology
- Molecular Pathology
- Translational Research
Background:
- Ovarian clear cell carcinoma (OCCC) represents about 5% of epithelial ovarian cancers (EOCs).
- OCCC typically presents at a younger age, earlier stage, and is associated with endometriosis.
- OCCC exhibits unique clinical behavior, molecular alterations, and pathogenesis compared to other EOC subtypes.
Purpose of the Study:
- To highlight the distinct molecular characteristics of OCCC.
- To emphasize the need for OCCC-specific research and treatment strategies.
- To underscore the importance of international collaboration for evidence collection.
Main Methods:
- Review of existing clinical and molecular data on OCCC.
- Comparative analysis of OCCC molecular alterations (e.g., SWI/SNF, PI3K/AKT, RTK/Ras pathways) versus other EOCs.
- Assessment of current treatment paradigms and their applicability to OCCC.
Main Results:
- OCCC rarely harbors BRCA1/BRCA2 mutations and has fewer CNVs.
- Key molecular alterations involve SWI/SNF, PI3K/AKT, and RTK/Ras signaling pathways.
- OCCC shows worse 5-year disease-specific survival compared to high-grade serous ovarian carcinomas (HGSOC).
Conclusions:
- Current EOC treatments, often based on HGSOC data, may not be optimal for OCCC.
- OCCC-specific diagnostic and therapeutic improvements require subtype-focused research.
- International collaboration and participation in histology-specific or basket trials are crucial for advancing OCCC care.
